US Patent 7763630 HIV integrase inhibitors
Patent 7763630 was granted and assigned to Bristol-Myers Squibb on July, 2010 by the United States Patent and Trademark Office.
All edits
Edits on 31 Oct, 2023
Golden AI
Edits made to:
Article (+344 characters)
Article
Patent abstract
The invention encompasses a series pyrimidinone compounds of Formula I which inhibit HIV integrase and prevent viral integration into human DNA. This action makes the compounds useful for treating HIV infection and AIDS. The invention also encompasses pharmaceutical compositions and methods for treating those infected with HIV.
Edits on 18 Sep, 2023
Golden AI
Edits made to:
Infobox (+3 properties)
Infobox
Patent Inventor Names
B. Narasimhulu Naidu0
Manoj Patel0
Margaret E. Sorenson0
Edits on 23 May, 2023
Golden AI
Edits made to:
Infobox (-1 properties)
Infobox
Official Website
Edits on 22 May, 2023
Golden AI
Edits made to:
Infobox (+1/-1 properties)
US Patent 07763630 HIV integrase inhibitors US Patent 7763630 HIV integrase inhibitors
Infobox
Patent Number
07763630
Patent Number
7763630
Edits on 3 Jun, 2022
Golden AI
Edits made to:
Infobox (+1 properties)
Infobox
Website URL
Edits on 5 Dec, 2021
Golden AI
Edits made to:
Infobox (+8 properties)
US Patent 07763630 HIV integrase inhibitors
Infobox
Is a
Current assignee
Patent jurisdiction
Patent number
07763630
Date of patent
July 27, 2010
Patent application number
12132145
Date Filed
June 3, 2008
Patent primary examiner
Find more entities like US Patent 7763630 HIV integrase inhibitors
Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
